BioCentury
ARTICLE | Financial News

Solid Biosciences upsizes IPO plans

January 24, 2018 7:49 PM UTC

Gene therapy company Solid Biosciences LLC (Cambridge, Mass.) amended its proposed IPO on NASDAQ, boosting both the price range and the number of shares it intends to offer. J.P. Morgan, Goldman Sachs, Leerink, Nomura and Chardan are underwriters.

Solid now hopes to sell 7 million shares at $18-$19. At $18.50, the company would raise $129.5 million and be valued at $616.8 million. The company initially proposed on Dec. 29 to raise $100 million. In a Jan. 16 amendment, Solid said it hoped to sell 5.9 million shares at $16-$18, which would raise roughly $100 million if priced at the midpoint...

BCIQ Company Profiles

Solid Biosciences Inc.